×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Cure Connections

Following a discussion on where to find reliable information on chronic lymphocytic leukemia (CLL) and treatment, participants share their closing thoughts.
Participants highlight the importance of proper support and communication while receiving therapy for chronic lymphocytic leukemia (CLL).
 
Considerations for what happens when a patient progresses with chronic lymphocytic leukemia (CLL).
 
Shared insight on the long-term nature of treatment for chronic lymphocytic leukemia (CLL).
 
More

Cure Expert Connections

Experts in the management of skin cancers discuss how to explain cutaneous squamous cell carcinoma (cSCC) to patients in the context of all skin cancers and consider CSCC risk factors and prevention tactics.
Perspectives on treatment decision-making in cutaneous squamous cell carcinoma, particularly regarding who is involved in selecting therapy.
Dr. Todd Schlesinger shares his experience with cemiplimab, an immunotherapy agent used to treat cutaneous squamous cell carcinoma.
 
Considerations for the use of immunotherapy, a novel approach to treatment, in patients with cutaneous squamous cell carcinoma.
 
More

Cure TV

Dr. Nancy U. Lin
“This is the first randomized trial to demonstrate an overall survival benefit for patients with brain metastases, which I think is very significant,” said Dr. Nancy U. Lin.
 
Conor Killmurray
While follow-up data on the BEACON CRC study demonstrated superior overall survival for certain patients with metastatic colorectal cancer receiving Braftovi, Mektovi and Erbitux, an exploratory analysis is needed to understand if this treatment can impact a wider subset of patients.
 
Dr. Eric Jonasch
The HIF-2a Inhibitor induced clinical responses among patients with von Hippel-Lindau disease–associated kidney cancer, according to results presented at the 2020 ASCO Virtual Scientific Program.
 
Dr. Ian Flinn
“We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about,” said Dr. Ian Flinn. Here more about this treatment in his interview with CURE®
 
More

Cure Speaking Out

Kristie L. Kahl and Jeremy Brauer
Dr. Jeremy Brauer, a spokesperson for the Skin Cancer Foundation, discusses the various ways the organization has raised awareness and education around skin cancer.
 
Kristie L. Kahl and Jeremy Brauer
Dr. Jeremy Brauer, a spokesperson for the Skin Cancer Foundation, talks about the current treatment strategies in skin cancer, and how immunotherapy and targeted agents have been a “game changer” for those with advanced disease.
 
Kristie L. Kahl and Jeremy Brauer
Dr. Jeremy Brauer, a spokesperson for the Skin Cancer Foundation, offers suggestions on how to conduct a thorough once-monthly self-examination to detect skin cancer early.
 
Kristie L. Kahl and Jeremy Brauer
Dr. Jeremy Brauer, a spokesperson for the Skin Cancer Foundation, discusses the different types of skin cancer, causes of the disease and who is at risk for developing it.
More
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×